Survivin peptide Sur1M2 in HLA-A*02:01 complex (Sur1M2/HLA-A2)

Survivin (BIRC5) is a member of the inhibitor of apoptosis (IAP) family that regulates both cell death and mitotic progression (UniProt: O15392). It is overexpressed in a wide range of malignancies but is nearly absent in normal adult tissues, providing a therapeutic window for oncology (PubMed: 10667338). The Sur1M2 antigen is a synthetic decapeptide (LMLGEFLKL) representing a modified version of the natural survivin 95-104 epitope, where a threonine-to-methionine substitution at position 2 increases its binding affinity for the HLA-A*02:01 molecule (PubMed: 11048911). This peptide-MHC complex serves as a target for immunotherapies, including peptide vaccines and T-cell receptor (TCR)-engineered T cells, which aim to trigger a cytotoxic T-lymphocyte response against tumor cells (PubMed: 15930334). Clinical trials have explored Sur1M2-based vaccines in patients with various cancers, including glioblastoma and melanoma, to evaluate their ability to induce survivin-specific immunity (ClinicalTrials.gov: NCT00108810). The specificity of this target is crucial for minimizing off-target effects, although potential expression in healthy stem cells remains a safety consideration.

Other names

Survivin(95-104) T96M peptide-HLA-A*02:01LMLGEFLKL-HLA-A2 complexBIRC5 peptide-MHC complexSur1M2-HLA-A2Survivin 95-104 modified peptide

Induction of cytotoxic T-lymphocyte (CTL) mediated lysis of tumor cells through T-cell receptor (TCR) recognition of the Sur1M2 peptide presented by HLA-A*02:01.